Format

Send to

Choose Destination
Iran J Kidney Dis. 2012 Sep;6(5):346-9.

Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children.

Author information

1
Aliasghar Children's Hospital, Tehran University of Medical Sciences, Tehran, Iran. anickavar@yahoo.com

Abstract

INTRODUCTION:

Management of frequently relapsing steroid-responsive or steroid-resistant idiopathic nephrotic syndrome (NS) in children has been a clinical challenge for pediatric nephrologists. In addition, adverse effects of long-term corticosteroids and cyclosporine administration emerge seeking a safe and effective treatment. The purpose of this study was to evaluate the safety and efficacy of mycophenolate mofetil (MMF) in these patients.

MATERIALS AND METHODS:

This study reviewed the outcomes of children with frequently relapsing or steroid-resistant idiopathic NS who were treated with MMF.

RESULTS:

A total of 36 patients (23 boys and 13 girls) were included. Their mean age at the time of diagnosis of NS was 61.94 ± 43.9 months. Of the children, 91.6% of those who had frequent relapses and 8.3% of those with steroid-resistant NS responded to MMF significantly (P < .001), with no significant association between age and gender with response to MMF. The treatment was well tolerated with no significant complications.

CONCLUSIONS:

In children with frequently relapsing NS, MMF was a safe and useful drug for maintaining remission, while it was of low value in children with steroid-resistant NS.

PMID:
22976259
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Iranian Society of Nephrology
Loading ...
Support Center